Literature DB >> 8960133

The importance of the ERCC1/ERCC4[XPF] complex for hypoxic-cell radioresistance does not appear to derive from its participation in the nucleotide excision repair pathway.

D Murray1, E Rosenberg.   

Abstract

The repair-deficient mutant rodent cell lines UV20 and UV41, which are defective in the ERCC1/ERCC4[XPF]-mediated 5'-endonuclease activity, are unusually sensitive to gamma-irradiation under hypoxic (but not oxic) conditions. Because this 5'-endonuclease appears to be involved in two distinct (but overlapping) DNA-repair pathways-the nucleotide excision repair pathway and the recombination-dependent pathway for the removal of DNA interstrand cross-links-it is unclear which of these defective activities is responsible for the hypoxic radiosensitivity of UV20 and UV41 cells. Accordingly, we have extended these measurements to the UV5 and UV24 lines which carry mutations in the ERCC2[XPD] and ERCC3[XPB] genes, respectively; both of these genes encode DNA helicases. These two mutants display a sensitivity to ultraviolet light that is similar to that of UV20 and UV41 cells, reflecting their defect in the incision step of the nucleotide excision repair pathway. However, neither UV5 nor UV24 cells are especially cross-sensitive to agents that produce DNA interstrand cross-links, suggesting that the ERCC2 and ERCC3 activities are not crucial for the repair of these lesions. We show that neither UV5 nor UV24 cells exhibit the unusual hypoxic radiosensitivity that characterizes UV20 and UV41 cells. Based on these data and on a comparison of the patterns of cross-sensitivity of these various mutants to other DNA-damaging agents, we conclude that the increased hypoxic radiosensitivity observed in the UV20 and UV41 mutants is due to a defect in the ERCC1/ERCC4-dependent pathway for the repair of DNA cross-links and not in the nucleotide excision repair pathway. The evidence suggests that this sensitivity may be mediated by some type of radiation-induced cross-links, possibly DNA-protein cross-links.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8960133     DOI: 10.1016/s0921-8777(96)00036-5

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  10 in total

Review 1.  The ERCC1 and ERCC4 (XPF) genes and gene products.

Authors:  Mandira Manandhar; Karen S Boulware; Richard D Wood
Journal:  Gene       Date:  2015-06-12       Impact factor: 3.688

2.  Prognostic value of ERCC1 in head and neck carcinoma treated with definitive or adjuvant radiotherapy.

Authors:  Vesna Bišof; Antonija Jakovčević; Sven Seiwerth; Zoran Rakušić; Slavko Gašparov
Journal:  J Cancer Res Clin Oncol       Date:  2012-09-26       Impact factor: 4.553

Review 3.  Update of prognostic and predictive biomarkers in oropharyngeal squamous cell carcinoma: a review.

Authors:  Carolin M Grimminger; Peter V Danenberg
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-09-09       Impact factor: 2.503

Review 4.  A genetic view of laryngeal cancer heterogeneity.

Authors:  María José de Miguel-Luken; Manuel Chaves-Conde; Amancio Carnero
Journal:  Cell Cycle       Date:  2016-03-03       Impact factor: 4.534

5.  Quantification of excision repair cross-complementing group 1 and survival in p16-negative squamous cell head and neck cancers.

Authors:  Ranee Mehra; Fang Zhu; Dong-Hua Yang; Kathy Q Cai; Joellen Weaver; Mahendra K Singh; Anna S Nikonova; Erica A Golemis; Douglas B Flieder; Harry S Cooper; Miriam Lango; John A Ridge; Barbara Burtness
Journal:  Clin Cancer Res       Date:  2013-10-02       Impact factor: 12.531

6.  Synergistic cytotoxicity and DNA strand breaks in cells and plasmid DNA exposed to uranyl acetate and ultraviolet radiation.

Authors:  Janice Wilson; Mary C Zuniga; Filbert Yazzie; Diane M Stearns
Journal:  J Appl Toxicol       Date:  2014-05-15       Impact factor: 3.446

7.  High ERCC1 expression predicts cisplatin-based chemotherapy resistance and poor outcome in unresectable squamous cell carcinoma of head and neck in a betel-chewing area.

Authors:  Tai-Jan Chiu; Chang-Han Chen; Chih-Yen Chien; Shau-Hsuan Li; Hsin-Ting Tsai; Yi-Ju Chen
Journal:  J Transl Med       Date:  2011-03-23       Impact factor: 5.531

8.  ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation.

Authors:  H J Jun; M J Ahn; H S Kim; S Y Yi; J Han; S K Lee; Y C Ahn; H-S Jeong; Y-I Son; J-H Baek; K Park
Journal:  Br J Cancer       Date:  2008-07-08       Impact factor: 7.640

9.  The prognostic value of excision repair cross-complementation group 1 (ERCC1) in patients with small cell lung cancer (SCLC) receiving platinum-based chemotherapy: evidence from meta-analysis.

Authors:  Yanlong Yang; Xiuping Luo; Nuo Yang; Ronghao Feng; Lei Xian
Journal:  PLoS One       Date:  2014-11-06       Impact factor: 3.240

10.  Excision repair cross-complementing group 2 upregulation is a potential predictive biomarker for oral squamous cell carcinoma recurrence.

Authors:  Yen-Yun Wang; Pen-Tzu Fang; Chang-Wei Su; Yuk-Kwan Chen; Joh-Jong Huang; Ming-Yii Huang; Shyng-Shiou F Yuan
Journal:  Oncol Lett       Date:  2021-04-07       Impact factor: 2.967

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.